LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22
Autor: | Egbert F. Smit, N. C. van Walree, K. Maas, J. Staal-van den Brekel, J. De Langen, Bonne Biesma, M. Youssef-ElSoud, W. Mellema, V. van Noord, Lizza E.L. Hendriks, Sjaak Burgers, A-M.C. Dingemans, S. Ernst, Thijo J N Hiltermann |
---|---|
Rok vydání: | 2021 |
Předmět: |
Oncology
Cisplatin medicine.medical_specialty Bevacizumab business.industry non-small cell lung cancer (NSCLC) Hematology medicine.disease_cause medicine.disease Carboplatin chemistry.chemical_compound Pemetrexed chemistry Paclitaxel Internal medicine Medicine KRAS business Chemotherapy naive medicine.drug |
Zdroj: | Annals of Oncology. 32:S1327 |
ISSN: | 0923-7534 |
Databáze: | OpenAIRE |
Externí odkaz: |